Zenas BioPharma, Valuation
| ZBIO Etf | USD 12.00 1.56 14.94% |
At this time, the etf appears to be overvalued. Zenas BioPharma, Common maintains a prevalent Real Value of $11.76 per share. The last-minute price of the etf is $12.0. Our model calculates the value of Zenas BioPharma, Common from examining the etf fundamentals such as Net Income of (37.12 M), total debt of 293.9 M, and Cash Flow From Operations of (30.53 M) as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Zenas BioPharma,'s price fluctuation is slightly risky at this time. Calculation of the real value of Zenas BioPharma, Common is based on 3 months time horizon. Increasing Zenas BioPharma,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Zenas BioPharma, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zenas Etf. However, Zenas BioPharma,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.0 | Real 11.76 | Hype 11.94 | Naive 9.88 |
The intrinsic value of Zenas BioPharma,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Zenas BioPharma,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Zenas BioPharma, Common helps investors to forecast how Zenas etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zenas BioPharma, more accurately as focusing exclusively on Zenas BioPharma,'s fundamentals will not take into account other important factors: Zenas BioPharma, Total Value Analysis
Zenas BioPharma, Common is at this time forecasted to have valuation of 0 with market capitalization of 673.29 M, debt of 293.9 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Zenas BioPharma, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 673.29 M | 293.9 M |
Zenas BioPharma, Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Zenas suggests not a very effective usage of assets in November.Zenas BioPharma, Profitability Analysis
Net Loss for the year was (37.12 M) with profit before overhead, payroll, taxes, and interest of 0.About Zenas BioPharma, Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Zenas BioPharma, Common. In general, an absolute valuation paradigm, as applied to this etf, attempts to find the value of Zenas BioPharma, Common based exclusively on its fundamental and basic technical indicators. By analyzing Zenas BioPharma,'s financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Zenas BioPharma,'s intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zenas BioPharma,. We calculate exposure to Zenas BioPharma,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zenas BioPharma,'s related companies.The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.